Discover why Hims & Hers Health (HIMS) remains a strong long-term buy after robust Q3 growth, new offerings, and expansion ...

Hims stock fell Tuesday following a mixed third-quarter report after the telehealth giant said it could soon sell Wegovy.

Shares of Hims & Hers Health ($HIMS) rallied on Tuesday after management said it’s in discussions with Novo Nordisk ($NVO) to ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

Hims and Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added ...

Hims and Hers Health Inc. rose after the telehealth company said it was in talks with Novo Nordisk A/S to sell its ...

Hims & Hers Health (NYSE:HIMS) said it is holding discussions with Novo Nordisk (NYSE:NVO) to make the Danish drugmaker's ...

Get key Q3 2025 earnings insights for Hims & Hers Health (HIMS): revenue growth, new partnerships, and global expansion plans.

Hims and Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added ...

Market observers now await further developments regarding the potential Novo Nordisk partnership. Should Hims & Hers successfully secure the Wegovy distribution agreement, the company could maintain ...

Live Updates Live Coverage Updates appear automatically as they are published. Get The Best Hims & Hers Live Earnings ...

Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar ...